MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma

Shile Zhang1, Jun S Wei2, Samuel Q Li2

  • 1Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA; Program in Bioinformatics, Boston University, Boston, MA 02218, USA.

Cancer Letters
|December 20, 2015
PubMed

Insights

MYCN drives aggressive neuroblastoma (NBL) by altering RNA splicing. Targeting key splicing factors like PTBP1 and HNRNPA1, regulated by MYCN, offers a potential therapeutic strategy for high-risk NBL.

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • Transcriptomics

Background:

  • MYCN amplification drives aggressive neuroblastoma (NBL).
  • The role of MYCN in regulating RNA splicing remains largely unknown.
  • Understanding MYCN's impact on splicing is crucial for NBL treatment.

Purpose of the Study:

  • To investigate the impact of MYCN on the RNA splicing program in stage 4 NBL.
  • To identify specific splicing factors and isoforms affected by MYCN.
  • To explore therapeutic targets within the MYCN-driven splicing network.

Main Methods:

  • High-throughput RNA sequencing of stage 4 MYCN-amplified NBL tumors and cell lines.
  • ChIP-sequencing to detect MYCN binding sites.
  • Differential gene expression and splicing analysis.
  • Functional knockdown experiments of splicing factors and downstream targets.

Main Results:

  • MYCN-amplified NBL exhibits a distinct splicing pattern impacting cancer hallmarks.
  • Six splicing factors showed differential expression, with MYCN directly regulating PTBP1 and HNRNPA1.
  • High expression of PTBP1 and HNRNPA1 correlated with poor patient survival.
  • Knockdown of PTBP1, HNRNPA1, and PKM2 repressed NBL cell growth.

Conclusions:

  • MYCN controls global RNA splicing in NBL by regulating key splicing factors.
  • This study reveals a novel role for MYCN in splicing, beyond transcription.
  • Targeting MYCN-regulated splicing factors presents a potential therapeutic avenue for high-risk NBL.

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.4K
RNA Splicing01:32

RNA Splicing

20.2K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
26.3K
Alternative RNA Splicing02:18

Alternative RNA Splicing

5.5K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
12.1K